IP Library Granted Patent US 6,989,373
Granted Patent B2
US 6,989,373 · App. 10/055,493 · Granted Jan 24, 2006

Method for restoring a fat-pad

Assignee: Bio Syntech Canada Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,989,373
App. No.
10/055,493
Granted
Jan 24, 2006
Kind
B2
Abstract

The present invention relates to a method for treating damaged or degenerated fat pads in a foot of a host in need thereof. The method comprises the step of injecting into the fat pad of the host a biocompatiable solution having physico-chemical and mechanical properties substantially similar to a fatty acid mixture normally present in a healthy fat pad.

Claims (29)

1. A method for treating a damaged or degenerated fat pad of a host in need thereof, said method comprising injecting into the fat pad of said host a biocompatible solution, with an intrinsic viscosity above 5 mPa·s at physiological temperature, wherein said solution is composed of at least one fatty acid selected from the group consisting of a natural or unnatural saturated fatty acid and a mono or poly unsaturated fatty acid.

2. The method of claim 1 , wherein the fat pad is located in the sub-calcaneal, outside arch or metatarsal of a foot.

3. The method of claim 1 , wherein the saturated fatty acid is selected from the group consisting of palmitate, stearate, and myristate, and acyclic, cyclic, heterocyclic, aromatic ester derivatives thereof, wherein the derivatives are selected from the group consisting of from hydroxy, acyloxy, aryloxy, amino, sulfhydryl, sulfonate, sulfate, phosphonate, phosphate, bis-, tris- and poly-phosphonates and phosphates, phosphatidyl, nucleosides, oligosaccharides, polysaccharides, and polyols.

4. The method of claim 1 , wherein the unsaturated fatty acid is selected from the group consisting of palmitoleate, oleate, vaccenate and linoleate, and acyclic, cyclic, heterocyclic, aromatic ester derivatives thereof, wherein the derivatives are selected from the group consisting of hydroxy, acyloxy, aryloxy, amino, sulfhydryl, sulfonate, sulfate, phosphonate, phosphate, bis-, tris- and poly-phosphonates and phosphates, phosphatidyl, nucleosides, oligosaccharides, polysaccharides, and polyols.

5. The method of claim 1 , wherein said solution is an autologous solution.

6. The method of claim 1 , wherein said solution comprises at least palmitate and oleoate.

7. The method of claim 1 , wherein said solution comprises a polymer and a metabolically absorbable liquid vehicle.

8. The method of claim 1 , wherein said solution comprises an aqueous liquid.

9. The method of claim 1 , wherein said solution comprises a non-aqueous liquid.

10. The method of claim 1 , wherein said solution forms a gel at a temperature above 30° C.

11. The method of claim 1 , wherein said solution is a thermo-gelling chitosan-based solution.

12. The method of claim 1 , wherein said solution comprises hyaluronic acid, and a metabolically absorbable liquid vehicle.

13. The method of claim 1 , wherein said solution comprises collagen, and a metabolically absorbable liquid vehicle.

14. The method of claim 1 , wherein said solution comprises components selected from the group consisting of fatty acids, thermogelling chitosan-based solution, collagen, hyaluronic acid, poly(ethylene glycol), and a metabolically absorbable liquid vehicle.

15. The method of claim 1 , wherein said solution is liquid at a temperature of and below 20 degrees Celsius, but forms a gel at temperatures above 30 degrees Celsius.

16. The method of claim 1 , wherein said solution is pre-heated at a temperature between 35 and 45 degrees Celsius to be liquid and injectable.

17. The method of claim 1 , wherein said solution is a gel at the time of injection.

18. The method of claim 1 , wherein said solution is injected into the fat pad by use of a syringe and a hypodermic needle.

19. The method of claim 1 , wherein said method is repeated periodically.

20. The method of claim 1 , wherein said fatty acids are mixed with a metabolically absorbable liquid vehicle.

21. The method of claim 20 , wherein the liquid vehicle is selected from the group consisting of water, alcoholic solvent, alkylene glycol and poly-alcohol.

22. The method of claim 20 , wherein the liquid vehicle is at least one member selected from the group consisting of ethanol, isopropyl alcohol, ethylene glycol and glycerol.

23. The method of claim 1 , wherein said solution becomes viscous or turns into a gel after injection.

24. The method of claim 23 , wherein the solution comprises monomers and/or oligomers, or a mixture of at least two different monomers and polymerises or co-polymerises within the pad after injection.

25. The method of claim 23 , wherein the solution comprises a viscous component mixed with a metabolically absorbable liquid vehicle, wherein after injection, the vehicle is absorbed in the host, thus increasing the concentration and hence the viscosity of the solution component.

26. The method of claim 1 , wherein the solution comprises a polymer.

27. The method of claim 26 , wherein the polymer is selected from the group consisting of cellulose, a substituted cellulose, poly(ethylene glycol) poly(propylene glycol), a copolymer of poly(ethylene glycol), a copolymer of poly(propylene glycol), a poly(ethylene glycol) copolymer with a poly(hydroxy acid), a poly(vinyl alcohol), or a poly(vinyl pyrrolidone), or a mixture thereof.

28. The method of claim 26 , wherein the biopolymer is selected from the group consisting of a polysaccharide and a polypeptide.

29. The method of claim 28 , wherein the biopolymer is selected from the group consisting of collagen, hyaluronic acid, poly(ethylene glycol), polylysine, gelatin, chitosan, alginate, and chondroitin sulfate.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2016
From: PIRAMAL HEALTHCARE (CANADA) LIMITED
To: SMITH & NEPHEW ORTHOPAEDICS AG
Reel/Frame 039937/0787 →
CORRECTIVE TO CORRECT INCORRECT APPLICATION NUMBERS RECORDED ON 10/26/201 REEL/FRAME 025192/0144 INCLUDING 60/733,173; 12/092,498; 61/032,610; 61/262,805; 61/262,808; 61/262,786; 61/262,758; 61/262,792; 12/092,498; 12/919,889. Recorded Apr 6, 2012
From: BIOSYNTEC CANADA INC.
To: PIRAMAL HEALTHCARE (CANADA) LTS.
Reel/Frame 028138/0935 →
ASSET PURCHASE AGREEMENT Recorded Oct 26, 2010
From: BIO SYNTECH CANADA INC.; BIOSYNTECH, INC.
To: PIRAMAL HEALTHCARE (CANADA) LTD.
Reel/Frame 025192/0144 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2004
From: DESROSIERS, ERIC A.
To: BIO SYNTECH CANADA INC.
Reel/Frame 014879/0884 →
Continuity (3)
Provisional Application 6024822800 · Nov 15, 2000
Provisional Application 6024857000 · Nov 16, 2000
Related Publication 20020094959A1 · Jul 18, 2002